Article Type
Changed
Fri, 01/26/2024 - 15:36

Timothy O'Brien, MD, shares his expectations for the upcoming 2023 AVAHO conference. Dr O'Brien highlights four key areas of interest: networking with providers from other VA systems; creating more clinical trial opportunities; exploring educational sessions on topics like AI in oncology and geriatric oncology; and fostering team building within the local VA group. With an area of focus in malignant hematology, particularly multiple myeloma, Dr O'Brien sees learning opportunities within the education sessions on geriatric oncology. Considering that the average age of patients with multiple myeloma at his institution is 70 years, he looks forward to gaining valuable strategies for geriatric assessment.

Publications
Sections

Timothy O'Brien, MD, shares his expectations for the upcoming 2023 AVAHO conference. Dr O'Brien highlights four key areas of interest: networking with providers from other VA systems; creating more clinical trial opportunities; exploring educational sessions on topics like AI in oncology and geriatric oncology; and fostering team building within the local VA group. With an area of focus in malignant hematology, particularly multiple myeloma, Dr O'Brien sees learning opportunities within the education sessions on geriatric oncology. Considering that the average age of patients with multiple myeloma at his institution is 70 years, he looks forward to gaining valuable strategies for geriatric assessment.

Timothy O'Brien, MD, shares his expectations for the upcoming 2023 AVAHO conference. Dr O'Brien highlights four key areas of interest: networking with providers from other VA systems; creating more clinical trial opportunities; exploring educational sessions on topics like AI in oncology and geriatric oncology; and fostering team building within the local VA group. With an area of focus in malignant hematology, particularly multiple myeloma, Dr O'Brien sees learning opportunities within the education sessions on geriatric oncology. Considering that the average age of patients with multiple myeloma at his institution is 70 years, he looks forward to gaining valuable strategies for geriatric assessment.

Publications
Publications
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
MDAngle
Gate On Date
Mon, 09/18/2023 - 14:45
Un-Gate On Date
Mon, 09/18/2023 - 14:45
Use ProPublica
CFC Schedule Remove Status
Mon, 09/18/2023 - 14:45
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Activity Salesforce Deliverable ID
399217.1
Activity ID
105715
Product Name
Research Capsule (ReCAP)
Product ID
80
Supporter Name /ID
Libtayo (Cemiplimab) [ 6480 ]